

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Apotex, Inc.,

Petitioner,

v.

UCB BIOPHARMA SPRL

Patent Owner.

Case IPR2019-00400

U.S. Patent No. 8,633,194

Title: Pharmaceutical composition of piperazine derivatives

**PATENT OWNER MANDATORY NOTICE INFORMATION UNDER 37
C.F.R. § 42.8**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

IPR2019-00400
Patent 8,633,194 B2

Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, UCB Biopharma Sprl (“UCB”), hereby files its Mandatory Notices:

A. Real Party-in-Interest (§ 42.8(b)(1))

The following real parties-in-interest are identified: UCB Biopharma Sprl, UCB, Inc., UCB Pharma S.A., UCB S.A, and UCB Manufacturing Inc.

B. Related Matters (§ 42.8(b)(2))

Patent owner is aware of the following district court litigations involving the '194 patent: *UCB, Inc. et al. v. Apotex Inc.*, No. 0-18-cv-60846 (S.D. Fla.); and *UCB, Inc. et al. v. Apotex Inc.*, 1:18-cv-03404 (S.D.N.Y.). Case No. 0-18-cv-60846 is currently pending. Case No. 1:18-cv-03404 has been voluntarily dismissed.

C. Counsel and Service Information (§§ 42.8(b)(3) and (4))

Patent owner identifies its lead and backup counsel as shown below:

Lead Counsel	Backup Counsel
James S. Trainor FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 921-2001 (tel) (650) 938-5200 (fax) jtrainor@fenwick.com USPTO Reg. No. 52,297	Robert E. Counihan FENWICK & WEST LLP 902 Broadway, Suite 14 New York, NY 10010 (212) 921-2001 (tel) (650) 938-5200 (fax) rcounihan@fenwick.com USPTO Reg. No. 61,382 Erica R. Sutter FENWICK & WEST LLP 801 California St. Mountain View, CA 94041

IPR2019-00400
Patent 8,633,194 B2

	(650) 988-8500 (tel) (650) 938-5200 (fax) esutter@fenwick.com USPTO Reg. No. 77,450
--	--

Please address all correspondence to the lead and backup counsel at the above addresses and to UCBXYZal@fenwick.com. Patent Owner consents to electronic service to the e-mail addresses above for lead and back-up counsel and to UCBXYZal@fenwick.com.

D. Patent Owner Preliminary Response

Patent Owner reserves the right to file a preliminary response at a separate date.

E. Patent Owner Power of Attorney

A Power of Attorney to transact all business in the United States Patent and Trademark office in connection with above-referenced *Inter Partes* Review from Patent Owner UCB Biopharma Sprl to the above-designated counsel at Fenwick & West LLP is being filed concurrently with these Mandatory Notices.

Dated: January 3, 2019

Respectfully submitted,

/s/ James S. Trainor
James S. Trainor (Reg. No. 52,297)
Robert E. Counihan (Reg. No. 61,382)
FENWICK & WEST LLP
902 Broadway, Suite 14
New York, NY 10010
(212) 921-2001

IPR2019-00400
Patent 8,633,194 B2

jtrainor@fenwick.com
rcounihan@fenwick.com

Erica R. Sutter (Reg. No. 77,450)
FENWICK & WEST LLP
801 California Street
Mountain View, CA 94041
(650) 988-8500
esutter@fenwick.com

Counsel for UCB Biopharma Sprl

IPR2019-00400
Patent 8,633,194 B2

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6 and 42.105, I hereby certify that on this 3rd day of January, 2019, the foregoing Patent Owner Mandatory Notice Information Under 37 C.F.R. § 42.8 and the associated Power of Attorney document were served on **January 3, 2019**, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Jitendra Malik, Ph.D.
Alissa M. Pacchioli
Joseph M. Janusz
Katten Muchin Rosenman LLP
550 S. Tryon Street, Suite 2900
Charlotte, NC 28202-4213
jitty.malik@kattenlaw.com
alissa.pacchioli@kattenlaw.com
joe.janusz@kattenlaw.com

Lance Soderstrom
Katten Muchin Rosenman LLP
575 Madison Avenue
New York, NY 10022-2585
lance.soderstrom@kattenlaw.com

Date: January 3, 2019

Respectfully submitted,

/s/ James S. Trainor (Electronically signed)
James S. Trainor (Reg. No. 52,297)

Counsel for UCB Biopharma Sprl